Company Financials

Monte Rosa Therapeutics, Inc. Financials

United States dollar

business Monte Rosa Therapeutics, Inc. Company Profile

Main Stock Listing

NASDAQ: GLUE

Market Capitalization None as of None

Market Cap History

Valuations Metrics as of May. 5, 2024

Trailing PE
Forward PE -2.49
Price to Sales TTM $
Price to Book MRQ $1.58
Enterprise to Revenue
Enterprise to EBITDA -0.71

Financial Reports as of Dec. 31, 2023

Financials

Fiscal Year Ends 2023-12-31
Most Recent Quarter 2023-12-31
Profit Margin 0.00%
Operating Margin 0.00%
Return on Assets TTM -27.72%
Return on Equity TTM -60.07%

Income Statement

Revenue TTM $0
Revenue per Share TTM $
Quarterly Revenue Growth %
Gross Profit TTM $0
EBITDA $-137,088,992
Net Income to Common TTM $-135,352,000
Diluted EPS TTM $-2.63
Quarterly Earnings Growth YoY %

Balance Sheet

Total Cash MRQ $232,412,992
Total Cash per Share MRQ $4.64
Total Debt MRQ $
Total Debt to Equity MRQ 25.68
Current Ratio MRQ 5.07
Book Value per Share MRQ $3.58

Cash Flow

Operating Cash Flow TTM $-43,802,000
Levered Free Cash Flow TTM $-55,470,376

GLUE Stock Info as of May. 5, 2024

Stock Statistics

Shares Outstanding 50,154,100
Float Shares 23,748,015
Avg 10 Volume 109,402
Avg 30 Volume None
Shares Short 1,866,469
Short Ratio 11.37
Short % of Shares 6.93%
% Held by Insiders 0.86%
% Held by Institutions 98.16%

Stock Price Summary

Beta 1.45
Fifty Two Week Low $2.44
Fifty Two Week High $8.84
Fifty Two Week Change 3.89%
Day 50 MA $6.44
Day 200 MA $5.45

Dividends and Splits

Forward Annual Dividend Rate $
Forward Annual Dividend Yield %
Trailing Annual Dividend Rate $0.00
Trailing Annual Dividend Yield 0.00%
Payout Ratio 0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date